AI-generated summary
The authors report a non-randomized case series of 10 patients with advanced ischemic heart failure who received 15 sessions of transcutaneous and intravenous photobiomodulation using red and infrared lasers. A six-minute walk test improved significantly at 3 months, while the rise in systolic ejection fraction was not statistically significant. The small sample and absence of a control group limit the conclusions.
- Participants
- 10
- Who or what was studied
- 10 patients with advanced ischemic heart failure (90% male, mean age 63.20 +/- 6.01 years)
- Wavelengths
- 658, 810 nm
- Limits stated in the abstract
- Small non-randomized case series of 10 patients without a control group, with the ejection fraction change not statistically significant.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 658 nm, 810 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.